Physician profile
John C Murphy
NPI 1669482428
$2,824.29
in general payments reported to CMS, 2019-2025
31 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $154 · 2021: $211 · 2022: $1,210 · 2023: $222 · 2024: $96.87 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $940.42 | 2022 | |
| Novo Nordisk INC | $571.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Stryker Corporation | $195.79 | 2019-2025 | Alphavent, Insignia |
| Amgen INC. | $112.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $100.97 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $97.34 | 2019-2025 | Rexulti |
| Abbott Laboratories | $96.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.12 | 2019-2020 | |
| Abbvie INC. | $64.78 | 2022-2025 | |
| Exact Sciences Corporation | $57.99 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $57.99 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $57.34 | 2019-2021 | |
| Pfizer INC. | $51.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $31.84 | 2022-2023 | Bexsero, Pediarix |
| Arbor Pharmaceuticals, INC. | $29.47 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.39 | 2022 | |
| Lundbeck LLC | $23.80 | 2021 | |
| Depuy Synthes Sales INC. | $23.43 | 2023 | Orthovisc, Monovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $22.56 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.13 | 2022 | |
| Bausch Health US, LLC | $16.94 | 2025 | Wellbutrin |
| Corcept Therapeutics | $16.01 | 2025 | Korlym |
| Pacira Pharmaceuticals Incorporated | $15.51 | 2024 | Iovera, Zilretta |
| Genentech USA, INC. | $14.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.53 | 2019 | |
| Redhill Biopharma INC. | $13.50 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2020 | |
| Adlon Therapeutics L.P. | $11.59 | 2021 | |
| Dynavax Technologies Corporation | $4.27 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.